click on circles to display study description...

SAVE-MORE, 2021 NCT04680949

anakinra (n=412) vs. placebo (n=194)

randomized controlled trial

100 mg anakinra once daily for 10 days

placebo

COVID 19 hospitalized

double-blind

12 patients withdrew consent and requested removal of alldata

CORIMUNO-ANA-1, 2021 NCT04341584

anakinra (n=59) vs. control (n=57)

randomized controlled trial

usual care plus anakinra (200 mg twice a day on days 1–3, 100 mg twice on day 4, 100 mg once on day 5)

usual care alone

COVID-19 mild to moderate

patients with mild-to-moderate COVID-19 pneumonia, severe acute respiratory syndrome coronavirus 2 infection confirmed by real-time RT-PCR, requiring at least 3 L/min of oxygen by mask or nasal cannula but without ventilation assistance, a score of 5 on the WHO Clinical Progression Scale (WHO-CPS), and a C-reactive protein serum concentration of more than 25 mg/L not requiring admission to the intensive care unit at admission to hospital

open-label

16 university hospitals in France